Herantis Pharma Plc
Press release 15 Sep 2020 at 09:00 am Eastern European Summer Time
Herantis Pharma Plc (“Herantis”) has published its newsletter for July–Sep 2020. The newsletter is also attached to this press release.
Julie Silber / Gabriela Urquilla
Tel: +46 (0)7 93 486 277 / +46 (0)72-396 72 19
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with ticker symbol “HRTIS” and Nasdaq First North Growth Market Sweden with ticker symbol “HRNTS”. Subscribe to Herantis’ news at https://herantis.com/subscribe/.